11:03 AM EDT, 06/24/2024 (MT Newswires) -- Anixa Biosciences ( ANIX ) said Monday it has treated the sixth patient in its phase 1 clinical study of a potential chimeric antigen receptor T-cell therapy for ovarian cancer.

The patient is anticipated to be the last patient in the second dosage group, the biotechnology company said.

Anixa said it would start enrolling patients in the third dosage group within July if patients in the second cohort observe no adverse effects.

The company is carrying out the trial through a research collaboration with Moffitt Cancer Center.

Anixa's stock was down 1.2% in recent Monday trading.

Price: 2.49, Change: -0.03, Percent Change: -1.19